Cimetidine increased steady state paroxetine concentrations by-%50 Cimetidine
Increases Sertraline AUC (50%) cmax(24%) and half-life (26%)
The pharmacologic effects of SSRI's may be decreased or reversed
Concurrent use may increase Citalopram levels.
Serious, sometimes fatal, reactions have occurred in patients receiving SSRI's in combinations with an MAOI an in patients who have recently discontinued the SSRI and then are started on an MAOI.
Phenobarbital decreased the AUC and half-life paroxetine by 25% and 38% respectively.
Phenytoin in reduced the AUC and half-life of Paroxetine by 50% and 35% respectively.
SSRI(Paroxetine and Fluoxetine)
Paroxetine reduced the AUC of phenytoin by 12%. Fluoxetine may increase hydantoin levels.
Smokers had a 25% increase in the metabolism of fluvoxamine
SSRI(Fluvoxamine, Fluoxetine, Paroxeline)
Concurrent use with fluoxetine or paroxetine may produce symptoms related to both central toxicity(e.g.headache, sweating, dizziness, agitation, restlessness),and peripheral toxicity(GI e.g. nausea, vomiting) concomittant use is not recommended. Tryptophan may enhance the sertonergic effect of fluvoxamine;use the combination with caution severe vomiting has been reproted with the coadministration of fluvoxamine and tryptophan
Although potentiation of impairment of mental and motor skills caused by alcohol has not occurred, concurrent use is not recommended in depressed patients.
Plasma TCA levels may be increased. Use caution when coadministering. Monitor TCA levels, may need to reduce TCA dose.
Plasma levels of Cisapride may be increased, resulting in QT prolongation or torsades de pointes, sometimes fatal. DO NOT USE CONCURRENTLY. Certrazine, fexofenadine, or loratadine may be safe alternative.
SSRI's (Fluvoxamine, Sertraline, Fluoxetine)
Clearance of benzodiazepines metabolized by hepatic oxidation may be decreased;those metabolized by glucuronidation are unlikely to be affected. Coadministration of alprazolam andfluoxetine has resultedin increased alprazolam levels and decreased psychomotor performances. Halve the initial alprazolam dose, and titrate to the lowest effective dose
Minimal propranolol levels has increased 5-fold;a slight potentiation of propranolol-induced reduction in heart rate and exercise diastolic blood pressure has occurred. Bradycardia and hypotensoin and a second case of orthostatic hypotension occurred with metoprolol, Atenolol levels were not affected. If coadministering, reduce initial beta blocker dose and be cautious in dose titration.
SSRI's (Fluoxetine, Fluvoxamine)
Effects of buspirone may be decreased. Plasma concentrations may be increased with fluvoxamine but clinical response may be decreased. Paradoxical worsening of OCD has occurred.
SSRI(Fluoxetine, Fluvoxamine, Citalopran)
Serum carbamazepine levels may be increased with Fluoxetine or fluvoxamine possibly resulting in toxicity. The clearance of Citalopram may be increased.
Drug Description Table 2
An elevated cyclosporin trough was reported in a 59-year old patient during concomitteant administration
Bradycardia has occurred with concurrent use.
SSRI's (Fluoxetine, Paroxetine)
Paroxetine decreased the AUC of digoxin by 15%. The concurrent administration of paroxetine and digoxin should be undertaken with caution.
SSRI's (Fluvuxamine, Fluoxetine)
Serum concentrations of haloperidol may be increased, recall memory and allentional function tests may be delayed.
SSRI's (Fluoxetine, Fluvoxamine, Citalopram)
Lithium levels may be increased or decreased by fluoxetine with possible neurotoxicity and serotonergic effects. In healthy volunteers, sertraline did no affect lithium levels. It is recommended that plasma lithium levels be monitored following initiation of sortraline, fluoxetine, and italopram with appropriate adjustments to lithium dose. Although no significant pharmacokinetic effects have been demonstrated, monitor plasma lithium levels. Concurrent use may enhance serotonergic effects of ciralopram. use caution with co-administering. Lithium may enhance the serotonergic effects of Huvoxamine, Use with caution in combination. seizures have been reported.
Significantly increased methadone (Plasma level: dose) ratios have occurred. One patient developed opioid intoxication, another had opioid withdrawal symptoms with fluvoxamine discontinuation.
A single case report has suggested possible additive effects of pimozide and fluoxetine leading to bradycardia.
Paroxetine increased the AUC, cmax and cmin of procyclidine by 35%, 36% and 67% respectively. Reduce procyclidine dose if anticholinergic effects occur.
Increased sedative-hypnotic effects may occur
Weakness, hyperreflexia, and incoordination have occurred with co-administration Observe patient closely.
Increased sensitivity to effect of sympathomimetics and increased serotonin sympathomimetics may occur.
Plasma tacrine concentrations may be elevated, increasing the pharmacologic and adverse effects.
Clearance of theophylline may be decreased by 3-fold. Reduce dosage. Elevated theophylline level have occurred with paroxetine. It is Recommended that theophylline levels be monitored when these drugs are concurrently administered.
In one study sertraline significantly decreased the clearance of Tolbutamude(16%) Clinical significance is unknown.
A pharmacodynamic interaction of altered anticoagulant effects including increased bleeding diathesis with unalterd prothrombin time (PT) may occur with paroxetine or fluoxetine.Concurrent administration of sertraline and warfarin and citalopram has resulted in an 8% and 5% increase in PT respectively, and delayed PT normalization. Fluvoxamine increased warfarin plasma levels by 98%. PT was prolonged.Monitor PT. Use caution with concomittant administration and monitor patient.
Inc. = Object drug increased Dec.= Object drug decreased Inc/Dec. = Undetermined clinical effect
Making Orange County a safe, healthy, and fulfilling place to live, work, and play, today and for generations to come, by providing outstanding, cost-effective regional public services.
You Are Now Leaving the County of Orange Official Portal